Cytogenetic effect of the anticancer drug epirubicin on Chinese hamster cell line in vitro

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 468, Issue 2, 2000, Pages 109-115

  El Mahdy Sayed Othman, Othman ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Chromosomal aberrations; Epirubicin; Mitotic index; SCEs

Indexed keywords

EPIRUBICIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHO CELL; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENOTOXICITY; IN VITRO STUDY; MITOSIS INDEX; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; CHO CELLS; CHROMOSOME ABERRATIONS; CHROMOSOMES; CRICETINAE; CRICETULUS; EPIRUBICIN; MITOTIC INDEX; MOLECULAR STRUCTURE; SISTER CHROMATID EXCHANGE;

EID: 0034632211     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(00)00047-4     Document Type: Article

References (26)

1. Sen P., Bailey N.M., Hagemeister F.B., Liang J.C. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res. 50:1990;558-562.
2. Chabner B.A., Myers C.E. Antitumor antibiotics. De Vita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 1993;374-385 A.J.F. Lippincott, Philadelphia.
3. Musilova J., Michalova K., Urban J. Sister-chromatid exchanges and chromosomal breakage in patients treated with cytostatics. Mutat. Res. 67:1979;289-294.
4. Rowley J.D., Golomb H.M., Vardiman J.W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 58(4):1981;759-767.
5. Pedersen-Bjergaard J., Philip P., Mortensen B.T., Ersboll J., Jensen G., Panduro J., Thomsen M. Acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood. 57(4):1981;712-723.
6. Whang-Peng J., Young R.C., Lee E.C., Longo D.L., Schechter D.L.G.P., De Vita V.T. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood. 71(2):1988;403-414.
7. Islam M.Q., Kopf I., Levan A., Granbrerg S., Friberg L.G., Levan G. Cytogenetic finding in 111 ovarian cancer patients: therapy-related chromosomal aberrations and heterochromatic variants. Cancer Genet. Cytogenet. 65:1993;35-46.
8. Nevstad N.P. Sister chromatid exchanges and chromosomal aberrations induced in human lymphocytes by the cytostatic drug adriamycin in vivo and in vitro. Mutat. Res. 57:1978;253-258.
9. Krishan A., Dutt K., Israel M., Ganapathi R. Comparative effects of adriamycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res. 41:1981;2745-2750.
10. Szabova E. Comparison of the in vitro effect of adriblastina on induction of SCEs in V79 cells and human peripheral blood lymphocytes. Neoplasma. 43(6):1996;407-409.
11. Aly M.S., Othman O.E., El Nahas S.M. Specific numerical chromosomal aberrations induced by adriamycin. Environ. Mol. Mutagen. 33:1999;161-166.
12. Echard G., Gellin J., Gillois M. Localisation des genes MPI, PKM2, NP sur le chromosome 3 du porc (Sus scrofa L.) et analyse cytogenetique d'une lignee de hamster chinois issue de la DON (wg3h). Genet. Sel. Evol. 16:1984;261-270.
13. Perry P., Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature. 251:1974;156-158.
14. Harris C.C. The carcinogenicity of anticancer drug: a hazard in man. Cancer. 37:1976;1014-1023.
15. Coleman C.N., Williams C.J., Flint A. Hematologic neoplasia in patients treated for Hodgkin's disease. N. Engl. J. Med. 297:1977;1249-1252.
16. Reimer R.R., Hoover R., Fraumeni J.F. Acute leukemia after alkylating-agent therapy of ovarian cancer. N. Engl. J. Med. 297:1977;177-181.
17. Dean B.J., Danford N. Assays for the detection of chemically-induced chromosome damage in cultured mammalian cells. Venitt S., Parry J.M., Rickwood D., Hames B.D. Mutagenicity Testing: A Practical Approach. 1984;187-232 Oxford, Washington, DC.
18. Benitez J., Carbonell F., Ferro T., Prieto F., Fayos J.S. Cytogenetic studies in 18 patients with secondary blood disorders. Cancer Genet. Cytogenet. 22:1986;309-317.
19. Pedersen-Bjergaard J., Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrom: correlation with clinical data for 61 consecutive cases. Br. J. Haematol. 66:1987;199-207.
20. Andersen M.K., Johansson B., Larsen S.O., Pedersen-Bjergaard J. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica. 83:1998;483-488.
21. William W.A., Hsu T.C. The genotoxic effects of adriamycin in somatic and germinal cells of the mouse. Mutat. Res. 79:1980;351-361.
22. Witt K.L., Bishop J.B. Mutagenicity of anticancer drugs in ammalian germ cells. Mutat. Res. 355:1996;209-234.
23. Newsome Y.L., Littlefield L.G. Adriamycin-induced chromosomal aberrations in human fibroblasts. J. Natl. Cancer Inst. 55(5):1975;1061-1064.
24. Tapiero H., Patet J., Fourcade A., Huppert J. Chromosomal changes associated with resistance to doxorubicin: correlation with tumorigenicity. Anticancer Res. 6:1986;203-208.
25. Rowley J.D., Golomb H.M., Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood. 50(5):1977;759-769.
26. Abraham S.K., Franz J. Induction of sister-chromatid exchanges by chemotherapeutic drugs in spermatogonia of mice: effects of procarbazine, adriamycin, cyclophosphamide and mitomycin C. Mutat. Res. 108:1983;373-381.